Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
£1.5m Contract renewal for Venn Life Sciences with a major global pharmaceutical client
AstraZeneca has decided to abandon the pledge of not-for profit made during the pandemic and aims to make a modest profit from COVID-19 vaccinations.
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2021.
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces it will release its interim results for the
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes the UK Health Security Agency’s Medical Devices (Coronavirus
Update on UK Availability of AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test following Implementation of CTDA Regulations
Agreement for Omega’s Market Leading, UK Manufactured VISITECT ® COVID-19 Antigen LFT
Every drug has its beneficiaries, whether they are suffering from a common chronic disease, a more severe form of cancer or a rare condition that affects 1 in 10,000 people. However,
DeepMatter Group PLC today announced it has signed a contract to trial its DigitalGlassware® platform with Aurigene Pharmaceutical Services based in Hyderabad, India, to supply its DigitalGlassware® platform.
News updates from both DeepVerge and Microsaic have been released this morning. Modern Water, a division of DeepVerge, announced a total of £2.2m of new orders for its enhanced monitoring
